Title:
CANCER COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE
Document Type and Number:
WIPO Patent Application WO/2020/059705
Kind Code:
A1
Abstract:
Provided is a method for using a STAT3 inhibitor having a high antineoplastic effect and few side effects. An antineoplastic agent obtained by combining a quinoline carboxamide derivative represented by formula (I) (where, R1, R2, R3, R4, R5, and R6 are the same or different, and indicate a hydrogen atom, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, COOR7 (where, R7 indicates a substituted or unsubstituted alkyl group), or OR8 (where, R8 indicates a substituted or unsubstituted alkyl group)) or a pharmaceutically acceptable salt thereof, with at least one cancer molecular targeted drug selected from an ALK inhibitor, an EGFR inhibitor, a multi-kinase inhibitor, an HER2/EGFR inhibitor, an mTOR inhibitor, a BRAF inhibitor, a MEK inhibitor, and a BCR-ABL inhibitor.
Inventors:
ASAI AKIRA (JP)
TSUGANE MOMOMI (JP)
KONISHI HIROAKI (JP)
YOSHINAGA AKIKO (JP)
TAKAHASHI HIROYUKI (JP)
IIJIMA TAKAHIRO (JP)
TSUGANE MOMOMI (JP)
KONISHI HIROAKI (JP)
YOSHINAGA AKIKO (JP)
TAKAHASHI HIROYUKI (JP)
IIJIMA TAKAHIRO (JP)
Application Number:
PCT/JP2019/036363
Publication Date:
March 26, 2020
Filing Date:
September 17, 2019
Export Citation:
Assignee:
YAKULT HONSHA KK (JP)
GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP)
GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP)
International Classes:
A61K31/436; A61K31/4709; A61K31/44; A61K31/4545; A61K31/47; A61K31/506; A61K31/517; A61K31/519; A61K31/5377; A61K45/00; A61P1/02; A61P1/16; A61P11/00; A61P15/00; A61P17/00; A61P35/00; A61P35/02; A61P43/00
Domestic Patent References:
| WO2010004761A1 | 2010-01-14 | |||
| WO2017076355A1 | 2017-05-11 |
Foreign References:
| JP2017530139A | 2017-10-12 | |||
| JP2015510879A | 2015-04-13 | |||
| JP2018504418A | 2018-02-15 | |||
| JPS5650529B2 | 1981-11-30 |
Other References:
MIYATA, HARUO ET AL., COMBINATION OF A STAT3 INHIBITOR AND AN MTOR INHIBITOR AGAINST A TEMOZOLOMIDE-RESISTANT GLIOBLASTOMA CELL LIN, vol. 14, no. 1, 2017, pages 83 - 91, XP055693923
MATSUNO, KENJI ET AL.: "Identification of a New Series of STAT3 Inhibitors by Virtual Screening", ACS MED. CHEM. LETT., vol. 1, no. 8, 2010, pages 371 - 375, XP009173598, DOI: 10.1021/ml1000273
ISLAM, RAFIQUL; HOSSAIN, IMRAN; OKAMOTO, YOSHINARI; NAGAMATSU, TOMOHISA; ANRAKU, KENSAKU; OKAWARA, TADASHI: "Facile Synthesis of 2- Phenylquinoline-4-Carboxamide Derivatives with Variant Structural Features", HETEROCYCLES, vol. 89, no. 3, 2014, pages 693 - 708, XP009526849, DOI: 10.3987/COM-14-12939
JIAN, KONG ET AL.: "YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma", MOLECULAR CANCER, vol. 13, no. 7, 2014, pages 1 - 11, XP021172561
HAO, YANG ET AL., ILEXGENIN A EXERTS ANTI- INFLAMMATION AND ANTI-ANGIOGENESIS EFFECTS THROUGH INHIBITION OF STAT3 AND PI3K PATHWAYS AND EXHIBITS SYNERGISTIC EFFECTS WITH SORAFENIB ON HEPATOMA GROWTH, vol. 315, 2017, pages 90 - 101, XP029879906
WEI-TIEN, TAI ET AL.: "Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1-Mediated Inhibition of STAT3", MOLECULAR CANCER THERAPEUTICS, vol. 11, no. 2, 2012, pages 452 - 463, XP055207188, DOI: 10.1158/1535-7163.MCT-11-0412
ASHIZAWA, TADASHI ET AL.: "Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 43, no. 1, 2013, pages 219 - 227, XP055693928
PHARMACOL REV, vol. 58, 2006, pages 621 - 681
See also references of EP 3854397A4
MATSUNO, KENJI ET AL.: "Identification of a New Series of STAT3 Inhibitors by Virtual Screening", ACS MED. CHEM. LETT., vol. 1, no. 8, 2010, pages 371 - 375, XP009173598, DOI: 10.1021/ml1000273
ISLAM, RAFIQUL; HOSSAIN, IMRAN; OKAMOTO, YOSHINARI; NAGAMATSU, TOMOHISA; ANRAKU, KENSAKU; OKAWARA, TADASHI: "Facile Synthesis of 2- Phenylquinoline-4-Carboxamide Derivatives with Variant Structural Features", HETEROCYCLES, vol. 89, no. 3, 2014, pages 693 - 708, XP009526849, DOI: 10.3987/COM-14-12939
JIAN, KONG ET AL.: "YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma", MOLECULAR CANCER, vol. 13, no. 7, 2014, pages 1 - 11, XP021172561
HAO, YANG ET AL., ILEXGENIN A EXERTS ANTI- INFLAMMATION AND ANTI-ANGIOGENESIS EFFECTS THROUGH INHIBITION OF STAT3 AND PI3K PATHWAYS AND EXHIBITS SYNERGISTIC EFFECTS WITH SORAFENIB ON HEPATOMA GROWTH, vol. 315, 2017, pages 90 - 101, XP029879906
WEI-TIEN, TAI ET AL.: "Dovitinib Induces Apoptosis and Overcomes Sorafenib Resistance in Hepatocellular Carcinoma through SHP-1-Mediated Inhibition of STAT3", MOLECULAR CANCER THERAPEUTICS, vol. 11, no. 2, 2012, pages 452 - 463, XP055207188, DOI: 10.1158/1535-7163.MCT-11-0412
ASHIZAWA, TADASHI ET AL.: "Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 43, no. 1, 2013, pages 219 - 227, XP055693928
PHARMACOL REV, vol. 58, 2006, pages 621 - 681
See also references of EP 3854397A4
Attorney, Agent or Firm:
THE PATENT CORPORATE BODY ARUGA PATENT OFFICE (JP)
Download PDF: